cAMPfield完成 1.8亿美元 A轮融资，以推进 prifemilast的研发，该药有望成为炎症性肠病（IBD）领域同类最佳的口服疗法-动脉网

cAMPfield Launches With $180 Million Series A to Advance Prifemilast, a Potential Best-in-Class Oral Therapy for IBD

PR Newswire 等信源发布 2026-06-18 19:58



可切换为仅中文







Oral PDE4 inhibitors have demonstrated efficacy in Phase 2 studies of ulcerative colitis

口服PDE4抑制剂在溃疡性结肠炎的II期研究中显示出疗效

cAMPfield's lead candidate is prifemilast, a potentially best-in-class PDE4 inhibitor for the treatment of IBD, in-licensed from Newsoara Biopharma Co., Ltd. (Newsoara)

cAMPfield 的主要候选药物是 prifemilast，这是一种从 Newsoara Biopharma Co., Ltd.（Newsoara）授权引进的潜在同类最优 PDE4 抑制剂，用于治疗炎症性肠病（IBD）。

Founded by Mountainfield Venture Partners in partnership with executives who played key roles in the development and/or commercialization of Humira

由Mountainfield Venture Partners与在Humira开发和/或商业化过程中发挥关键作用的高管合作创立

, Entyvio

, Otezla

，奥泰拉

and Zeposia

以及泽波西亚

Series A led by Frazier Life Sciences and included Deep Track Capital, Forbion, Abingworth, Venrock, Longitude Capital, Novo Holdings and RA Capital

A轮融资由Frazier Life Sciences领投，Deep Track Capital、Forbion、Abingworth、Venrock、Longitude Capital、Novo Holdings和RA Capital参投。

cAMPfield initiating global Phase 2 trials in moderate-to-severe ulcerative colitis and Crohn's disease

cAMPfield 启动针对中重度溃疡性结肠炎和克罗恩病的全球 II 期临床试验

SAN DIEGO

圣迭戈

，

June 18, 2026

2026年6月18日

/PRNewswire/ -- cAMPfield Therapeutics, Inc., a clinical-stage biopharmaceutical company formed to develop well-tolerated and highly effective oral medicines for immune-mediated inflammatory diseases, has launched with a $180 million Series A financing to advance prifemilast (HY1999/HPP737), a once-daily oral PDE4 inhibitor, for the treatment of inflammatory bowel disease (IBD).

/美通社/ -- cAMPfield Therapeutics, Inc. 是一家处于临床阶段的生物制药公司，旨在开发耐受性良好且高效的治疗免疫介导炎症疾病的口服药物。该公司已正式启动运营，并完成1.8亿美元A轮融资，以推进每日一次口服PDE4抑制剂prifemilast（HY1999/HPP737）用于治疗炎症性肠病（IBD）。

The Series A financing was supported by top tier investors led by Frazier Life Sciences, and included Deep Track Capital, Forbion, Abingworth, Venrock, Longitude Capital, Novo Holdings, and RA Capital..

A轮融资由顶级投资机构Frazier Life Sciences领投，参投方包括Deep Track Capital、Forbion、Abingworth、Venrock、Longitude Capital、Novo Holdings和RA Capital。

Recent proof-of-concept data support the therapeutic potential of PDE4 inhibition in ulcerative colitis and underscore this mechanism's potential to address persistent unmet needs in IBD. To advance a next-generation PDE4 inhibitor with the potential to deliver improved efficacy and tolerability, Mountainfield Venture Partners founded cAMPfield Therapeutics based on an exclusive license to global rights outside of Greater China from Newsoara to prifemilast (originally developed and licensed to Newsoara by vTv Therapeutics Inc.)..

近期的概念验证数据支持PDE4抑制在溃疡性结肠炎中的治疗潜力，并强调该机制在解决炎症性肠病（IBD）领域持续存在的未满足需求方面的潜力。为推进一种有望提高疗效和耐受性的下一代PDE4抑制剂，Mountainfield Venture Partners基于从Newsoara获得的除大中华区以外的全球独家许可，成立了cAMPfield Therapeutics，该许可涉及prifemilast（最初由vTv Therapeutics Inc.开发并授权给Newsoara）。

Prifemilast is an investigational, once-daily PDE4B-selective inhibitor that has an extensive development history in the United States and China, with more than 700 clinical trial participants dosed to date, including more than 250 participants with 52 weeks of exposure. Prifemilast has shown more selective inhibition of PDE4B, the subtype most strongly associated with beneficial anti-inflammatory activity, vs PDE4D, a subtype believed to contribute to dose-limiting adverse effects.

普非米拉斯特是一种在研的每日一次PDE4B选择性抑制剂，在美国和中国拥有广泛的开发历史，迄今已有超过700名临床试验受试者接受给药，其中包括超过250名暴露时长达52周的受试者。与被认为会导致剂量限制性不良反应的PDE4D亚型相比，普非米拉斯特对与有益抗炎活性最密切相关的PDE4B亚型显示出更高的选择性抑制作用。

Prifemilast has been well-tolerated, with treatment discontinuation rates comparable to those observed for participants on placebo. It has also demonstrated robust efficacy in a Phase 3 trial for plaque psoriasis, an immune-mediated inflammatory disease with overlapping inflammatory pathways, cytokine networks, and genetic risk factors with IBD.

普里非米拉斯特耐受性良好，其治疗中止率与安慰剂组参与者相当。在针对斑块状银屑病（一种与炎症性肠病具有重叠的炎症通路、细胞因子网络和遗传风险因素的免疫介导性炎症性疾病）的III期临床试验中，该药也显示出显著的疗效。

Taken together, the extensive clinical experience with prifemilast supports its potential to deliver the combination of efficacy, tolerability, and convenience needed to establish a new standard of care in IBD. Building on these encouraging clinical data, cAMPfield is initiating a global Phase 2b trial with prifemilast in moderate-to-severe ulcerative colitis and a global Phase 2 trial in Crohn's disease..

综上所述，普里费米拉斯特广泛的临床经验支持其具备提供疗效、耐受性和便利性组合的潜力，从而有望确立炎症性肠病（IBD）治疗的新标准。基于这些令人鼓舞的临床数据，cAMPfield 公司正在启动普里费米拉斯特治疗中重度溃疡性结肠炎的全球 IIb 期临床试验，以及治疗克罗恩病的全球 II 期临床试验。

'Despite the availability of more than a dozen approved therapies for IBD, most patients fail to achieve deep and durable remission, while others discontinue or switch treatments because of limitations in safety or long-term effectiveness,' said Bill Gerhart, CEO of cAMPfield Therapeutics. 'Supported by the clinical validation of PDE4 inhibition, the best-in-class potential of prifemilast, and our team's deep experience in IBD drug development, we aim to establish prifemilast as the treatment of choice for patients and physicians seeking robust disease control with a convenient once-daily, well-tolerated oral therapy.'.

“尽管目前有十多种获批的炎症性肠病（IBD）治疗药物，但大多数患者未能实现深度且持久的缓解，而其他患者则因安全性或长期疗效方面的局限而停止或更换治疗方案，”cAMPfield Therapeutics 首席执行官 Bill Gerhart 表示。“在 PDE4 抑制作用的临床验证、prifemilast 的同类最佳潜力以及我们团队在 IBD 药物开发方面的深厚经验的支持下，我们旨在将 prifemilast 确立为患者和医生寻求稳健疾病控制时的首选治疗方案，该方案为每日一次、耐受性良好的口服疗法。”

cAMPfield was founded by Mountainfield Venture Partners, a biopharmaceutical company creation firm, in partnership with industry leaders who have played key roles in the development and commercialization of important therapies for IBD and other immune-mediated inflammatory diseases. The company's founders include Asit Parikh, formerly Head of Gastroenterology at Takeda Pharmaceuticals and development leader of Entyvio; Keith Usiskin, formerly VP and Head of Gastroenterology at Celgene / Bristol Myers Squibb and development leader of Otezla and Zeposia for IBD; and Mark Stenhouse, formerly COO of Prometheus Biosciences (developer of tulisokibart) and VP of U.S.

cAMPfield 由生物制药企业创立公司 Mountainfield Venture Partners 与在炎症性肠病（IBD）及其他免疫介导炎症性疾病的重要疗法开发和商业化过程中发挥关键作用的行业领袖合作创立。公司创始人包括：前武田制药胃肠病学负责人及 Entyvio 的开发领导者 Asit Parikh；前 Celgene / Bristol Myers Squibb 副总裁兼胃肠病学负责人、IBD 药物 Otezla 和 Zeposia 的开发领导者 Keith Usiskin；以及前 Prometheus Biosciences（tulisokibart 的开发商）首席运营官兼美国区副总裁 Mark Stenhouse。

Sales and Marketing at AbbVie with responsibility for Humira commercialization..

在艾伯维负责修美乐商业化工作的销售与市场部门。

The company is led by Chief Executive Officer Bill Gerhart, a Senior Advisor at Mountainfield Venture Partners. Prior to cAMPfield, Gerhart served as Chief Executive Officer of Kinevant, Respivant, Patara Pharma, Elevation Pharmaceuticals, and Mpex Pharmaceuticals, where he helped build and lead companies developing innovative therapies for inflammatory, respiratory, rare, and infectious diseases.

该公司由首席执行官比尔·格哈特（Bill Gerhart）领导，他同时也是Mountainfield Venture Partners的高级顾问。在加入cAMPfield之前，格哈特曾担任Kinevant、Respivant、Patara Pharma、Elevation Pharmaceuticals和Mpex Pharmaceuticals的首席执行官，在这些公司中，他帮助建立并领导了开发针对炎症、呼吸系统、罕见病和传染病创新疗法的企业。

Throughout his career, he has advanced multiple clinical-stage programs and led successful strategic transactions resulting in approved and commercialized therapies for patients with serious diseases..

在他的职业生涯中，他推动了多个临床阶段项目的发展，并主导了成功的战略交易，最终为患有严重疾病的患者带来了获批并实现商业化的疗法。

About Inflammatory Bowel Disease

关于炎症性肠病

Inflammatory Bowel Disease, which includes ulcerative colitis and Crohn's disease, is an immune-mediated inflammatory disease that affects more than 2.4 million people in the United States and remains an area of substantial unmet need. Although numerous therapies are available, remission remains elusive for many, and treatment discontinuation, loss of response, and safety concerns continue to drive frequent therapy switching.

炎症性肠病（包括溃疡性结肠炎和克罗恩病）是一种免疫介导的炎症性疾病，在美国影响超过240万人，且仍存在巨大的未满足医疗需求。尽管已有多种疗法可供使用，但许多患者仍难以实现缓解，而治疗中断、疗效丧失以及安全性问题继续促使频繁更换治疗方案。

While injectable biologics have grown in use, many patients and clinicians prefer the convenience and familiarity of oral therapies. However, currently approved oral therapies for IBD are limited by poor tolerability, safety concerns and/or modest efficacy..

尽管注射用生物制剂的使用日益增长，但许多患者和临床医生更倾向于口服疗法的便利性和熟悉度。然而，目前获批用于炎症性肠病（IBD）的口服疗法受限于耐受性差、安全性问题和/或疗效有限。

About Phosphodiesterase 4 Inhibitors

关于磷酸二酯酶4抑制剂

Inhibiting phosphodiesterase 4 (PDE4) increases intracellular cyclic adenosine monophosphate (cAMP), which in turn reduces pro-inflammatory cytokines, increases anti-inflammatory cytokines, and modulates fibrotic pathways. PDE4 inhibitors are a validated class of medicines for treating immune-mediated inflammatory and fibrotic diseases, with regulatory approvals thus far in plaque psoriasis, psoriatic arthritis, Behcet's disease, COPD and pulmonary fibrosis.

抑制磷酸二酯酶4（PDE4）可增加细胞内环磷酸腺苷（cAMP），进而减少促炎性细胞因子，增加抗炎性细胞因子，并调节纤维化通路。PDE4抑制剂是一类经证实可用于治疗免疫介导的炎症性和纤维化疾病的药物，目前已获得监管机构批准用于斑块状银屑病、银屑病关节炎、白塞病、慢性阻塞性肺疾病（COPD）和肺纤维化的治疗。

PDE4 inhibitors have also demonstrated clinically meaningful efficacy in Phase 2 studies of ulcerative colitis, but none have yet been advanced to Phase 3 studies or regulatory approvals. While effective, the clinical use of earlier generation PDE4 inhibitors has been limited by poor tolerability that results from the inhibition of multiple isoforms, or subtypes, of PDE4..

PDE4抑制剂在溃疡性结肠炎的2期临床研究中也显示出具有临床意义的疗效，但尚未有任何药物进入3期临床研究或获得监管批准。尽管早期一代PDE4抑制剂有效，但其临床应用因耐受性差而受到限制，这种不良耐受性源于对PDE4多种同工酶（或亚型）的抑制。

About cAMPfield Therapeutics

关于 cAMPfield Therapeutics

cAMPfield Therapeutics is a clinical-stage biopharmaceutical company focused on developing well-tolerated and highly effective oral medicines for immune-mediated inflammatory diseases, including inflammatory bowel disease. cAMPfield was founded by Mountainfield Venture Partners in partnership with executives who played key roles in the development and/or commercialization of Entyvio, Humira, Otezla and Zeposia.

cAMPfield Therapeutics 是一家处于临床阶段的生物制药公司，专注于开发耐受性良好且疗效显著的口服药物，用于治疗包括炎症性肠病在内的免疫介导性炎症疾病。cAMPfield 由 Mountainfield Venture Partners 联合在 Entyvio、Humira、Otezla 和 Zeposia 的开发和/或商业化过程中发挥关键作用的高管共同创立。

cAMPfield holds exclusive global development and commercialization rights to prifemilast outside Greater China through a license agreement with Newsoara..

cAMPfield通过与Newsoara的许可协议，拥有prifemilast在大中华区以外的全球独家开发和商业化权利。

The company is headquartered in San Diego, California. For more information, visit

公司总部位于加利福尼亚州圣地亚哥。欲了解更多信息，请访问

www.campfieldtx.com

。

About Newsoara Biopharma Co., Ltd.

关于新索拉生物制药有限公司

Newsoara Biopharma Co., Ltd. (Newsoara) is a clinical-stage biopharmaceutical company founded in 2018 with headquarters in Shanghai, China. Newsoara focuses on discovering and developing innovative, targeted therapies to treat autoimmune diseases, cancer, and metabolic disorders.

新索拉生物制药有限公司（Newsoara）是一家临床阶段的生物制药公司，于2018年成立，总部位于中国上海。Newsoara专注于发现和开发创新靶向疗法，用于治疗自身免疫性疾病、癌症和代谢紊乱。

About vTv Therapeutics Inc.

关于 vTv Therapeutics Inc.

vTv Therapeutics Inc. (vTv) is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv's clinical pipeline is led by

vTv Therapeutics Inc.（vTv）是一家处于后期阶段的生物制药公司，专注于开发口服小分子候选药物，旨在帮助治疗糖尿病及其他慢性病患者。vTv 的临床研发管线由

cadisegliatin

卡迪塞利亚汀

, currently in a US Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes.

，目前正处于美国III期临床试验阶段，是一种正在研究用于治疗1型糖尿病的潜在首创口服葡萄糖激酶激活剂。

About Mountainfield Venture Partners

关于 Mountainfield Venture Partners

Mountainfield Venture Partners is a biopharmaceutical company creation firm that builds new companies around development-stage drug candidates with the potential to transform patient care. Mountainfield forms its companies around in-licensed drug candidates, world-class leadership teams, and syndicated capital raises from top-tier life science institutional investors.

Mountainfield Venture Partners 是一家生物制药公司创建机构，围绕具有变革患者护理潜力的开发阶段药物候选者构建新公司。Mountainfield 通过授权引进的药物候选者、世界级的领导团队以及来自顶级生命科学机构投资者的联合资本募集来组建其公司。

For more information, visit .

更多信息，请访问。

www.mountainfieldvp.com

。

Media and Investor Contact

媒体与投资者联系

Rayne Rodgers

雷恩·罗杰斯

[email protected]

cAMPfield Therapeutics

cAMPfield 治疗公司